CAD-031 powder (2071209-49-7)

CAD-031 powder (CAD031) is a novel brain penetrant, J147-derivative that has enhanced neurogenic activity over J147 in human neural precursor cells (NPCs); also stimulates the division of NPCs in the subventricular zone of old APPswe/PS1E9 mice; rescues primary cortical neurons from oxytosis, and effectively reduce oxidative stress with EC50 of 20 nM; also prevents loss of energy metabolism that leads to neuron cell death in an in vitro ischemia model with EC50 of 47 nM; target fatty acid metabolism and inflammation, exhibits therapeutic efficacy on cognitive and physiological parameters in mouse model of AD.

Manufacture:  Batch Production
Package:  1KG/bag, 25KG/drum
Wisepowder has the capability to produce and supply large quantity. All production under cGMP condition and strict quality control system, all testing documents and sample available.

CAD-031 powder (2071209-49-7) video


CAD-031 powder (2071209-49-7) Base Information

Name CAD-031 powder
CAS 2071209-49-7
Purity 98%
Chemical name Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-[[3-(trifluoromethoxy)phenyl]methylene]hydrazide
Synonyms CAD 31);CAD-031 (CAD031
Molecular Formula C18H14F6N2O2
Molecular Weight 404.312
Melting Point No Data
InChI Key No Data
Form No Data
Appearance No Data
Half Life No Data
Solubility No Data
Storage Condition -20°C 12 Months; 4°C 6 Months
Application No Data
Testing Document Available


CAD-031 powder (2071209-49-7) General Description

CAD-031 powder were favorable in the context of preventing some of the toxic events in old age-associated neurodegenerative diseases. CAD-031 powder has potent neuroprotective properties in six distinct nerve cell assays that mimic toxicities observed in the old brain. Pharmacological and preliminary toxicological studies show that CAD-031 is brain-penetrant and likely safe. When fed to old, symptomatic APPswe/PS1ΔE9 AD mice starting at 10 months of age for 3 additional months in a therapeutic model of the disease, there was a reduction in the memory deficit and brain inflammation, as well as an increase in the expression of synaptic proteins. Small-molecule metabolic data from the brain and plasma showed that the major effect of CAD-031 is centered on fatty acid metabolism and inflammation. Pathway analysis of gene expression data showed that CAD-031 had major effects on synapse formation and AD energy metabolic pathways.


CAD-031 (2071209-49-7) Application

  1. CAD-031 is broadly neuroprotective
  2. CAD-031 has an excellent pharmacological and safety profile
  3. CAD-031 reverses some aspects of cognitive dysfunction in old transgenic AD mice
  4. RNA-seq analysis suggests that CAD-031 modulates inflammation, synaptic health, and metabolism
  5. CAD-031 reduces inflammation and increases markers for neurogenesis and synapses
  6. AD-31 targets lipid metabolism


CAD-031 (2071209-49-7) Reference

  1. Daugherty D, et al. Alzheimers Res Ther. 2017 Jul 14;9(1):50.
  2. Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, et al. A novel neurotrophic drug for cognitive enhancement and Alzheimer’s disease. PLoS One. 2011;6(12):e27865. doi: 10.1371/journal.pone.0027865. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  3. Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther. 2013;5(3):25. doi: 10.1186/alzrt179. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  4. Prior M, Chiruta C, Currais A, Goldberg J, Dargusch R, Maher P, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014;5(7):503– doi: 10.1021/cn500051h. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  5. Prior M, Goldberg J, Chiruta C, Farrokhi C, Kopynets M, Roberts AJ, et al. Selecting for neurogenic potential as an alternative for Alzheimer’s disease drug discovery. Alzheimers Dement. 2016;12(6):678– doi: 10.1016/j.jalz.2016.03.016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  6. Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, et al. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging. 2015;7(11):937– doi: 10.18632/aging.100838. [PMC free article] [PubMed] [CrossRef] [Google Scholar]


Trending Articles